Crossmark

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line

Crossref DOI link: https://doi.org/10.1186/s12885-018-4995-0

Published Online: 2018-11-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Seung Tae

Kim, Sun Young

Lee, Jeeyun

Kim, Kyung

Park, Se Hoon

Park, Young Suk

Lim, Ho Yeong

Kang, Won Ki

Park, Joon Oh
Funding

Funding for this research was provided by:

Ministry of Health & Welfare, Republic of Korea (HI14C2640, HI14C3418, HI16C2750)

National Research Foundation of Kore (2016R1A6A3A11934805, and 2016R1A6A3A11932444)

Samsung Medical Center (GF01140111)
License Information

Text and Data Mining valid from 2018-11-12
More Information

Article History

Received: 23 March 2018

Accepted: 24 October 2018

First Online: 12 November 2018

Ethics approval and consent to participate

: Our investigation was conducted in accordance with contemporary ethical standards, the Declaration of Helsinki, and national and international guidelines. This study was approved by the authors’ institutional review board (Samsung Medical Center).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.